While it isn’t clear what triggered the $82 million payment, the announcement comes a week after AbbVie said that its Parkinson’s disease candidate tavapadon—which it secured from the $8.7 billion acquisition of Cerevel—cleared a Phase III study.
While it isn’t clear what triggered the $82 million payment, the announcement comes a week after AbbVie said that its Parkinson’s disease candidate tavapadon—which it secured from the $8.7 billion acquisition of Cerevel—cleared a Phase III study.